BayPAT’s Licensee Recardio already in Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin in Europe and USA

BayPAT, a service provider offering services in the area of technology transfer, IP management and commercialisation, today announced that its licensee Recardio is already in the Phase 2 study for regenerative therapy in early recovery post-myocardial infarction in Europe and USA.

The regenerative therapy concept of Recardio with its DPP-IV inhibitor dutogliptin is subject to a licence agreement concluded in 2012 between BayPAT and Recardio and is based on an invention originating from Ludwig-Maximilians-University of Munich.

The clinical study is intended to evaluate the safety and efficacy of Recardio’s lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement. Specialized cardiology centers located throughout Europe and USA have enrolled patients and are meanwhile actively recruiting. Roman Schenk, Recardio’s founder and Chairman, remarked that the enrollment of all planned 140 patients will proceed until early 2020 and outcomes will be available shortly afterwards.


The regenerative therapeutic approach of Recardio to minimize and repair the heart muscle injury that follows an infarction consists of mobilizing, recruiting, and homing stem cells in vivo by using cytokines and inhibitors. Specifically, the growth of stem cells and improvement of cardiac function is achieved by the mobilization of stem cells from the bone marrow using G-CSF. The mobilized stem cells enter the bloodstream and are directed to the site of myocardial injury by dutogliptin. Dutogliptin is a small molecule inhibitor of dipeptidyl peptidase-IV (DPP4). It is responsible for the activation of stromal derived factor-1α (SDF-1α), a cytokine responsible for the binding of circulating stem cells in the area of ischemic injury.

“We are very happy that BayPAT was able to partner with a competent company such as Recardio, to bring this innovative therapeutic approach into the clinic and thus making a valuable contribution to achieve significant progress in the field of treatment of myocardial infarction.” said Dr. Robert Phelps, BayPAT’s Chief Executive Officer.

More information about the clinical program is available by visiting the “clinicaltrials.gov” website at the following link: https://clinicaltrials.gov/ct2/show/NCT03486080

About Recardio

Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.  For more information, visit: http://www.recardio.eu/

Über die Bayerische Patentallianz GmbH

Bayerische Patentallianz GmbH (BayPAT) was founded in 2007 by the Universität Bayern e.V. and the Hochschule Bayern – the Bavarian Universities of Applied Sciences – e.V. as the central patent and marketing agency to foster technology transfer of Bavarian Universities, University Hospitals and Universities of Applied Sciences and is responsible for 33 research institutes. Under the umbrella of the Bavarian Research and Innovation Agency (BayFIA), BayPAT (www.baypat.de) is a full-service technology management provider offering services in the areas of technology transfer, IP management and IP commercialisation. Key clients are the Bavarian Universities, University Hospitals and Universities of Applied Sciences and its over 25,000 associated scientists, as well as non-university research institutes, industry and independent inventors worldwide. Main focus in assessing and exploiting IP are the areas of biotechnology, chemistry, medical engineering, physics, automotive industry, energy and environment engineering, information and communication technology as well as mechanical engineering.

Firmenkontakt und Herausgeber der Meldung:

Bayerische Patentallianz GmbH
Prinzregentenstr. 52
80538 München
Telefon: +49 (89) 5480177-0
Telefax: +49 (89) 5480177-99
http://www.baypat.de

Ansprechpartner:
Dr. Robert Phelps
CEO
Telefon: +49 (89) 5480177-10
E-Mail: rphelps@baypat.de
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel